SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
May 25, 2004
DYAX CORP.
(Exact name of registrant as specified in its charter)
Delaware | | 000-24573 | | 04-3053198 |
(State or other jurisdiction of
incorporation or organization) | | (Commission file number) | | (IRS employer identification
number) |
300 Technology Square, Cambridge, MA 02139
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code:
(617) 225-2500
Item 5. Other Events.
On May 25, 2004, Dyax Corp. issued a press release announcing that, pending further preclinical review, DX-88 has been placed on clinical hold. A copy of that press release is attached as Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
99.1 Press release of Dyax Corp., dated May 25, 2004.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DYAX CORP. |
| |
| |
Dated: May 25, 2004 | By: | /s/ Stephen S. Galliker | |
| | Stephen S. Galliker |
| | Executive Vice President, Finance
and Administration, and Chief
Financial Officer |
3
EXHIBIT INDEX
Exhibit
No. | | Description |
| | |
99.1 | | Press release of Dyax Corp., dated May 25, 2004. |
4
